|
News For MRK;PFE;GSK;JNJ;BMY;NVS;SHPG;ABT;CELG;SNY From The Last 14 Days Check below for free stories on MRK;PFE;GSK;JNJ;BMY;NVS;SHPG;ABT;CELG;SNY the last two weeks. |
|
|
| May 10, 2013 |
| 06:16 EDT |  | JNJ | Obesity surgery booming in India, Bloomberg reports
 Subscribe for More Information |
|
| 05:42 EDT |  | SHPG | Shire downgraded to Neutral from Overweight at JPMorgan
|
|
| 05:42 EDT |  | NVS | Novartis drug Ilaris approved by FDA
Subscribe for More Information |
|
| May 9, 2013 |
| 17:09 EDT | | JNJ | Johnson & Johnson deal to settle sales practices probe stalls, WSJ reports
Johnson & Johnson's $2.2B settlement with the Justice Department related to its promotion of certain drugs is on hold as the company is looking to avoid language in the agreement that could make it vulnerable to private lawsuits, reports The Wall Street Journal, citing people familiar with the talks. Reference Link |
|
| 12:24 EDT | | SHPG | Shire unit wins patent trial against Watson regarding LIALDA
Shire (SHPG), announces that its subsidiary, Shire Development, has prevailed in its litigation against Watson Pharmaceuticals, Watson Laboratories-Florida, Watson Pharma. and Watson Laboratories in connection with their Abbreviated New Drug Application for a generic version of Shire's LIALDA delayed release tablets for the induction of remission in adults with active, mild to moderate ulcerative colitis and for the maintenance of remission of ulcerative colitis. Following a five day bench trial in the Southern District of Florida, Judge Middlebrooks issued a ruling upholding the validity of the patent covering LIALDA, US Patent No. 6,773,720, and holding that the proposed ANDA formulation infringes the claims of that patent. Accordingly, Judge Middlebrooks confirmed that Shire is entitled to an injunction, which he will issue separately, which prohibits the FDA from approving the ANDA formulation until the expiration of the '720 patent. |
|
| 10:17 EDT | | PFE, BMY, SHPG | Shire trades higher in London amid takeover chatter, Guardian says
Subscribe for More Information |
|
| 09:51 EDT | | JNJ | J&J unit says first patient enrolled in reMARQable study
Subscribe for More Information |
|
| 07:22 EDT | | MRK | Merck awarded significant portion of UNICEF HPV vaccine tender
Subscribe for More Information |
|
| 07:04 EDT | | ABT | Abbott announces CE Mark for A1c test
Subscribe for More Information |
|
| May 8, 2013 |
| 10:33 EDT | | PFE, BMY | Bristol-Myers, Pfizer announced results from ARISTOTLE trial subanalysis
Bristol-Myers (BMY) and Pfizer (PFE) announced yesterday that results from a prespecified subanalysis of the ARISTOTLE trial were published in Circulation, the peer-reviewed journal of the American Heart Association. Results from the subanalysis showed that the reductions in stroke or systemic embolism, number of major bleeding events and mortality demonstrated with Eliquis compared to warfarin in the ARISTOTLE trial were consistent across subgroups defined based on levels of International Normalized Ratio control in patients with nonvalvular atrial fibrillation. This story corrects a headline from yesterday. |
| |
| 08:32 EDT | | MRK | Merck says FDA accepts biologics license application for allergy tablet
Merck announced that the Biologics License Application for its investigational ragweed pollen sublingual allergy immunotherapy tablet has been accepted for review by the U.S. Food and Drug Administration. The BLA for Merck’s investigational ragweed pollen sublingual allergy immunotherapy tablet is supported by five studies evaluating the efficacy and safety of the tablet in adults, 18 years of age or older, with ragweed induced allergic rhinitis. On March 27, Merck announced that the FDA had also accepted the BLA for its investigational Timothy grass pollen sublingual allergy immunotherapy tablet. Merck expects the FDA’s review for both to be completed in the first half of 2014. |
|
| 07:38 EDT |  | JNJ | BofA/Merrill's medical tech analyst hold an analyst/industry conference call
Subscribe for More Information |
|
|
|
|
|
